Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma

被引:17
|
作者
Caviglia, Gian Paolo [1 ]
Ciruolo, Michela [2 ]
Olivero, Antonella [1 ]
Carucci, Patrizia [2 ]
Rolle, Emanuela [2 ]
Rosso, Chiara [1 ]
Abate, Maria Lorena [1 ]
Risso, Alessandra [2 ]
Ribaldone, Davide Giuseppe [1 ,2 ]
Tandoi, Francesco [3 ]
Saracco, Giorgio Maria [1 ,2 ]
Bugianesi, Elisabetta [1 ,2 ]
Gaia, Silvia [2 ]
机构
[1] Univ Turin, Dept Med Sci, I-10100 Turin, Italy
[2] Citta Salute & Sci Univ Hosp, Div Gastroenterol, I-10100 Turin, Italy
[3] Citta Salute & Sci Univ Hosp, Dept Surg Sci, Gen Surg 2U, Liver Transplant Unit, I-10100 Turin, Italy
关键词
AFP; BCLC; biomarker; HCC; PIVKA-II; prognosis; POSITIVE TUMOR-MARKERS; LIVER FIBROSIS; PIVKA-II; AFP; MODEL;
D O I
10.3390/cancers12102776
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The prognosis of hepatocellular carcinoma is mainly driven by the stage of the tumor and by the overall liver function status. However, survival rates of patients with hepatocellular carcinoma are heterogeneous. In this study, we investigated whether circulating biomarkers might allow us to stratify the survival of patients with a new diagnosis of hepatocellular carcinoma. We observed that three biomarkers (namely AFP, PIVKA-II, and CYFRA 21-1) were independent predictors of overall survival. In addition, the combined use of these biomarkers allowed us to further stratify patients with hepatocellular carcinoma, according to their survival probability. This approach might help clinicians to tailor more personalized treatment strategies. Keratin 19 (K19) is a cancer stem cell marker expressed by a subpopulation of hepatocellular carcinoma (HCC), associated with tumor aggressiveness. We evaluated the prognostic value of serum K19 fragment (CYFRA 21-1), in comparison or in combination with alpha-fetoprotein (AFP) and protein induced by vitamin-K absence or antagonist-II (PIVKA-II), in patients with HCC. A total of 160 patients (28F/132M; median age 62, range 44-86 years) with a new diagnosis of HCC and available serum samples collected at tumor diagnosis were analyzed retrospectively. Median overall survival (OS) after HCC diagnosis was 35.1, 95% CI 27.1-70.5 months. Multivariate Cox regression analysis showed that CYFRA 21-1 > 2.7 ng/mL (hazard ratio (HR) = 3.39, p < 0.001), AFP > 20 ng/mL (HR = 2.27, p = 0.007), and PIVKA-II > 200 mAU/mL (HR = 2.17, p = 0.020) were independent predictors of OS. The combination of biomarkers positivity allowed us to stratify patients with HCC into four risk categories associated with a progressively lower survival probability (log-rank test, p < 0.001). CYFRA 21-1 resulted an independent prognostic factor of patients with HCC and its combination with AFP and PIVKA-II might be useful to tailor personalized treatment strategies.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [1] Clinical significance of serum cytokeratin-19 fragment (CYFRA 21-1) in hepatocellular carcinoma
    Uenishi, Takahiro
    Yamazaki, Osamu
    Yamamoto, Takatsugu
    Hirohashi, Kazuhiro
    Tanaka, Hiromu
    Tanaka, Shogo
    Hai, Seikan
    Ono, Koichi
    Kubo, Shoji
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY, 2006, 13 (03): : 239 - 244
  • [2] Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer
    Wu, Hua-Hsi
    Wang, Peng-Hui
    Yeh, Jiun-Yih
    Chen, Yi-Jen
    Yen, Ming-Shyen
    Huang, Rui-Lan
    Tsai, Yueh-Ju
    Yuan, Chiou-Chung
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2014, 53 (01): : 30 - 34
  • [3] Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma
    Caviglia, Gian Paolo
    Olivero, Antonella
    Ciruolo, Michela
    Carucci, Patrizia
    Rolle, Emanuela
    Rosso, Chiara
    Abate, Maria Lorena
    Risso, Alessandra
    Younes, Ramy
    Smedile, Antonina
    Saracco, Giorgio Maria
    Bugianesi, Elisabetta
    Gaia, Silvia
    JOURNAL OF HEPATOLOGY, 2020, 73 : S372 - S373
  • [4] Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer
    Morita, T
    Kikuchi, T
    Hashimoto, S
    Kobayashi, Y
    Tokue, A
    EUROPEAN UROLOGY, 1997, 32 (02) : 237 - 244
  • [5] Cutaneous apocrine carcinoma with elevated serum cytokeratin 19 fragment 21-1 (CYFRA 21-1)
    Fujioka, Mao
    Kato, Junji
    Sumikawa, Yasuyuki
    Sato, Sayuri
    Sawada, Masahide
    Uhara, Hisashi
    JOURNAL OF DERMATOLOGY, 2019, 46 (10): : E387 - E388
  • [6] Reference Intervals of Cytokeratin-19 Fragment (CYFRA 21-1) in Healthy Adults in China
    Dai, Yunhai
    Qu, Wei
    Sang, Shibiao
    Tao, Shaoneng
    Li, Yan
    Wang, Yan
    Li, Qingru
    Wu, Tingting
    Zhu, Anyou
    Chen, Qing
    Song, Jiaqi
    Li, Qing
    Ji, Yongliang
    Zheng, Yijie
    Wang, Fengchao
    CLINICAL LABORATORY, 2018, 64 (1-2) : 123 - 133
  • [7] Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer
    T Uenishi
    S Kubo
    K Hirohashi
    H Tanaka
    T Shuto
    T Yamamoto
    S Nishiguchi
    British Journal of Cancer, 2003, 88 : 1894 - 1899
  • [8] Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer
    Uenishi, T
    Kubo, S
    Hirohashi, K
    Tanaka, H
    Shuto, T
    Yamamoto, T
    Nishiguchi, S
    BRITISH JOURNAL OF CANCER, 2003, 88 (12) : 1894 - 1899
  • [9] Serum and tissue distribution of a fragment of cytokeratin 19 (cyfra 21-1) in lung cancer patients
    Quillien, V
    Ramee, MP
    Bansard, JY
    Meritte, H
    Briens, E
    Logeais, Y
    Langanay, T
    Corbineau, H
    Dazord, L
    ANTICANCER RESEARCH, 1995, 15 (6B) : 2857 - 2863
  • [10] Cytokeratin fragment 19 (CYFRA 21-1) in healthy smokers
    Kao, CH
    Hsieh, JF
    Ho, YJ
    Tsai, SC
    Lee, JK
    ANTICANCER RESEARCH, 1999, 19 (5C) : 4545 - 4546